Related by context. All words. (Click for frequent words.) 71 Myelodysplastic Syndrome MDS 71 Gleevec resistant 70 colon carcinoma 70 Aflibercept 70 Amrubicin 70 refractory chronic lymphocytic 70 CHOP chemotherapy 70 SNT-MC#/idebenone 70 receptor tyrosine kinase inhibitor 70 cell lymphoma CTCL 70 sunitinib Sutent 70 lymphoid malignancies 70 Diffuse Large B 69 metastatic renal cell 69 cutaneous T 69 Aplidin 69 hA# 69 malignant ascites 69 mRCC 69 previously untreated follicular 69 CLL SLL 69 leukemia AML 69 recurrent glioblastoma 69 alkylating agent 69 refractory colorectal cancer 69 thalidomide Thalomid 69 metastatic malignant 69 dasatinib Sprycel 69 Evoltra ® 69 indolent NHL 69 relapsed multiple myeloma 69 Ceflatonin 69 undergoing hematopoietic stem 69 metastatic renal cell carcinoma 69 recurrent glioblastoma multiforme 69 Epratuzumab 69 lumiliximab 68 demonstrated antitumor activity 68 systemic ALCL 68 MGd 68 Arzerra ofatumumab 68 OHR/AVR# 68 epithelial tumors 68 galiximab 68 metastatic gastric 68 refractory acute myeloid 68 gefitinib Iressa 68 CYT# potent vascular disrupting 68 Vidaza azacitidine 68 pancreatic adenocarcinoma 68 antibody MAb 68 GW# [003] 68 gastrointestinal stromal tumors GISTs 68 Nexavar sorafenib 68 biliary tract cancer 68 BrachySil TM 68 pancreatic carcinoma 68 relapsed leukemia 68 SPRYCEL ® 68 ELACYT 68 leukemia CLL 68 generation purine nucleoside 68 Dacogen injection 68 haematologic malignancies 68 lymphoma CTCL 68 Personalized Immunotherapy 68 vidofludimus 68 alvespimycin 68 pediatric acute lymphoblastic 67 metastatic carcinoma 67 Cimzia TM 67 castrate resistant prostate cancer 67 tumors GIST 67 Fludara ® 67 metastatic GIST 67 Archexin 67 Torisel 67 Velcade bortezomib 67 HER2 positive metastatic breast 67 pain palliation 67 Proxinium TM 67 metastatic colorectal carcinoma 67 YONDELIS 67 gastrointestinal stromal tumor GIST 67 Annamycin 67 haematological cancers 67 HuMax CD4 67 hypereosinophilic syndrome 67 recurrent NSCLC 67 gemcitabine Gemzar ® 67 depsipeptide 67 prostate carcinoma 67 PEGylated Fab fragment 67 metastatic colorectal 67 SCCHN 67 volociximab 67 hematological malignancy 67 Genentech Rituxan 67 R sorafenib tablets 67 PI3K/Akt pathway inhibitor 67 interleukin IL -# 67 hypomethylating agent 67 refractory cutaneous T 67 FOLOTYN ® 67 RANK Ligand inhibitor 67 Factor VIIa 67 lintuzumab SGN 67 docetaxel Taxotere ® 67 kidney urologic 67 idiopathic thrombocytopenic purpura ITP 67 bendamustine 67 CTAP# Capsules 67 cetuximab Erbitux 67 Genasense ® 67 ospemifene 67 relapsing remitting MS RRMS 67 Chronic lymphocytic leukemia CLL 67 Dacogen decitabine 67 systemic anaplastic large 67 IV Busulfex 67 mitoxantrone plus 67 acyclovir Lauriad R 67 forodesine 67 colorectal carcinoma 67 docetaxel Taxotere R 67 HRPC 67 bevacizumab Avastin ® 67 SSc 66 Pemetrexed 66 Hsp# Inhibitor 66 Xanafide 66 advanced metastatic renal 66 cetuximab Erbitux R 66 PNP inhibitor 66 novel VDA molecule 66 mTOR inhibitor 66 Cutaneous T 66 rituximab refractory 66 FOLFOX chemotherapy 66 Insegia 66 multi kinase inhibitor 66 metastatic bladder 66 Rituxan rituximab 66 Sudhir Agrawal D.Phil 66 Chronic Lymphocytic Leukemia CLL 66 UPLYSO 66 EGFR TKI 66 Panzem R NCD 66 Daclizumab 66 pan HDAC inhibitor 66 papillary renal cell carcinoma 66 erlotinib Tarceva ® 66 follicular Non Hodgkin 66 assessing T DM1 66 sorafenib tablets 66 Pathway Inhibitor 66 dasatinib Sprycel ® 66 vinca alkaloid 66 imatinib Gleevec ® 66 chimeric monoclonal antibody 66 omacetaxine mepesuccinate 66 pegylated liposomal doxorubicin 66 antiangiogenic agent 66 enzastaurin 66 beta 1a 66 rALLy clinical trial 66 eritoran 66 sorafenib Nexavar 66 huC# DM4 66 Relapsed Refractory 66 ZACTIMA 66 trastuzumab Herceptin R 66 Interferon beta 66 refractory CLL 66 oropharyngeal candidiasis OPC 66 elacytarabine 66 metastatic CRC 66 Kit CD# positive 66 metastatic neuroendocrine tumors 66 thetreatment 66 polycythemia vera essential thrombocythemia 66 relapsed refractory 66 Gleevec imatinib mesylate 66 gastrointestinal stromal tumors GIST 66 Hodgkin lymphoma HL 66 glioblastoma multiforme GBM 66 mTOR mammalian target 66 Hepatocellular Carcinoma HCC 66 relapsed MM 66 Zybrestat 66 Gleevec Glivec 66 cutaneous T cell 66 ThermoDox R 66 PKC# 66 EGFR mutation positive 66 Neulasta ® 66 myeloid metaplasia 66 histone deacetylase inhibitor 66 esophageal candidiasis 66 docetaxel Taxotere 66 refractory NSCLC 66 Fludara 66 luteinizing hormone releasing 66 ovarian carcinoma 66 LEUKINE 66 Aviptadil 66 AKT inhibitor 66 AEG# 66 Gleevec imatinib 66 Taxotere docetaxel 66 anthracycline taxane 66 opioid induced constipation OIC 66 non metastatic osteosarcoma 66 Doxil ® 66 Tarceva TM 66 MAGE A3 66 CD# antibody [001] 66 novel therapeutic antibodies 66 Virulizin ® 66 Troxatyl 66 IMiDs R 66 gastrointestinal stromal tumors 66 Cloretazine R 66 Octreolin 66 diarrhea predominant irritable 66 proteasome inhibitor 66 SNT MC# 65 immunotherapeutic agent 65 humanised monoclonal antibody 65 skeletal metastases 65 paclitaxel Taxol ® 65 Multiple Myeloma MM 65 oral JAK#/JAK# inhibitor 65 Sutent sunitinib 65 Acute Myeloid Leukemia AML 65 acetonide FA 65 huN# DM1 65 allogeneic bone marrow 65 Alocrest 65 immune thrombocytopenic purpura ITP 65 investigational therapies 65 TEMODAL 65 pertuzumab 65 miglustat 65 Tasimelteon 65 Janus Kinase 65 Cloretazine ® 65 Cloretazine 65 MYLOTARG 65 mertansine 65 ON #.Na 65 lenalidomide Revlimid R 65 RhuDex ® 65 Nexavar tablets 65 IAP inhibitor 65 HuMax EGFr 65 plus prednisone 65 BCR ABL inhibitor 65 Friedreich Ataxia FRDA 65 JAK inhibitor 65 tyrosine kinase inhibitor TKI 65 BCG refractory 65 Fibrillex TM 65 chronic lymphocytic leukemia CLL 65 Advanced Renal Cell 65 nonmetastatic 65 metaglidasen 65 multikinase inhibitor 65 decitabine 65 targeted radiotherapeutic 65 follicular lymphoma FL 65 Fludarabine 65 hepatocellular carcinoma HCC 65 trabectedin 65 unresectable stage 65 Leukine ® 65 AAG geldanamycin analog 65 leukemia ALL 65 bortezomib Velcade 65 T#I [002] 65 Irinotecan 65 MAGE A3 ASCI 65 calcineurin inhibitor 65 relapsed refractory multiple myeloma 65 elotuzumab 65 IV NSCLC 65 Golimumab 65 histone deacetylase HDAC inhibitor 65 Plicera 65 alefacept 65 B CLL 65 myelodysplastic myeloproliferative diseases 65 Kinoid 65 Onconase 65 OMP #R# 65 ara C 65 Enzastaurin 65 including eniluracil ADH 65 gemcitabine Gemzar 65 leukaemias 65 Chronic Lymphocytic Leukemia 65 malignant pleural mesothelioma 65 CVP chemotherapy 65 novel histone deacetylase 65 Campath ® 65 BRAF inhibitor 65 trastuzumab Herceptin ® 65 chemoresistant 65 Erbitux cetuximab 65 IgG1 monoclonal antibody 65 baminercept 65 nilotinib Tasigna 65 interferon gamma 1b 65 LymphoStat B belimumab 65 Telintra 65 Ecallantide 65 refractory CTCL 65 advanced hepatocellular carcinoma 65 TREANDA 65 panitumumab Vectibix 65 IMA# 65 Tarceva erlotinib 65 Raptiva ® 65 Zarnestra 65 VitiGam 65 endometrial adenocarcinoma 65 deforolimus 65 neovascular diseases 65 PDX pralatrexate 65 Certican 65 humanized anti 65 Decitabine 65 PROSTVAC VF 65 cetuximab Erbitux ® 65 GvHD 65 recurrent metastatic 65 Orally administered 65 refractory metastatic 65 Ribavirin causes 65 ATL# [001] 65 TBC# 65 phase IIb clinical 65 IL# PE#QQR 65 concurrent chemoradiation 65 exocrine pancreatic insufficiency EPI 65 tyrosine kinase inhibitor 65 Pertuzumab 65 BRIM2 65 TORISEL 65 EGFR HER2 65 Luteinizing Hormone Releasing Hormone 65 Silodosin 65 liposomal formulation 65 induced macular edema 65 Panzem 65 small molecule Hedgehog 65 invasive candidiasis 65 Arranon 64 motesanib 64 haematologic 64 Vandetanib 64 castrate resistant 64 biologic therapy 64 mitogen activated ERK kinase 64 small lymphocytic lymphoma 64 Pirfenidone 64 Kepivance 64 anti angiogenic therapy 64 Certolizumab pegol 64 histamine dihydrochloride 64 factor VIIa 64 liposomal doxorubicin 64 metastatic hormone refractory 64 mouse xenograft models 64 ZOLINZA 64 prostate cancer mCRPC 64 colorectal cancer liver metastases 64 Chronic lymphocytic leukemia 64 refractory multiple myeloma 64 CML CP 64 Azacitidine 64 metastatic RCC 64 immunomodulatory therapy 64 cilengitide 64 Eribulin 64 orally administered inhibitor 64 immune modulating 64 chronic myeloid 64 Peginterferon alfa 2b 64 Pralatrexate 64 Mantle Cell Lymphoma 64 estramustine 64 Behcet uveitis 64 TroVax ® 64 relapsed ALL 64 basiliximab 64 Cinquil 64 SIR Spheres 64 radiation sensitizer 64 monoclonal anti 64 AVASTIN 64 pulmonary arterial hypertension PAH 64 essential thrombocythemia ET 64 amrubicin 64 NV1FGF 64 Xelox 64 imatinib mesylate 64 mCRC patients 64 investigational monoclonal antibody 64 IRX 2 64 idiopathic myelofibrosis 64 stage IIIb IV 64 Seliciclib 64 dacarbazine DTIC 64 HSP# inhibitor 64 methylnaltrexone 64 EOquin TM 64 Hodgkin lymphoma NHL 64 CIMZIA TM certolizumab pegol 64 milatuzumab 64 Campath alemtuzumab 64 Evoltra TM 64 metastatic pancreatic 64 antibody MT# 64 IMiDs ® 64 acute promyelocytic leukemia APL 64 HQK 64 superficial bladder cancer 64 anti angiogenic agent 64 refractory APL 64 Cx# [002] 64 gemcitabine carboplatin 64 Apaziquone 64 TG# [003] 64 oral prodrug 64 targeted antifolate 64 LHRH receptor positive 64 A1PI 64 anthracycline containing 64 sargramostim 64 Zalypsis 64 EGS# 64 androgen independent 64 imatinib Gleevec 64 p# biomarker 64 zalutumumab 64 aurora kinase 64 sunitinib malate 64 riociguat 64 Vidaza R 64 imatinib resistant 64 PD LID 64 MyVax R 64 hormone LHRH antagonist 64 hepatocellular cancer 64 Kamada AAT 64 Cimzia ® certolizumab pegol 64 non hodgkin lymphoma 64 Quinamed 64 Phase IIb clinical trials 64 ixabepilone 64 ACTEMRA TM 64 adjuvant cisplatin 64 metastatic malignant melanoma 64 alpha antagonist 64 Neupogen ® 64 ofatumumab 64 acute myeloid 64 Omacetaxine 64 mapatumumab 64 romidepsin 64 erlotinib Tarceva 64 histologic subtype 64 Squalamine 64 oropharyngeal candidiasis 64 hepatorenal syndrome 64 OMP #M# 64 EGFR expressing mCRC 64 TTR gene 64 PSMA ADC 64 PF # [002] 64 RezularTM 64 refractory metastatic colorectal cancer 64 FOLFIRI alone 64 allogeneic cell 64 visilizumab 64 tumorigenicity 64 ErbB2 positive 64 KRAS mutant 64 SUTENT ® 64 VELCADE melphalan 64 Romiplostim 64 NSCLC 64 PEG SN# 64 DXL# 64 FRDA 64 fluoropyrimidine 64 MKC# MT 64 BR.# 64 Advagraf 64 DU #b 64 patients receiving myelosuppressive 64 bladder carcinoma 64 hormone refractory metastatic prostate 64 SAR# [004] 64 Navelbine ® 64 Prodarsan R 64 OncoVex 64 adecatumumab 64 Actemra tocilizumab 64 refractory Hodgkin 64 5 Fluorouracil 64 EndoTAG TM -1 64 malignant lymphomas 64 Clolar ® 64 Ph + acute lymphoblastic 64 Aryplase 64 adult chronic ITP 64 isoform selective 64 refractory acute promyelocytic 64 myeloproliferative diseases 64 humanised antibody 64 TheraCIM h R3 64 reslizumab 64 intravesical therapy 64 PANVAC VF 64 carcinoembryonic antigen 64 Allovectin 7 64 chronic myeloid leukemia CML 64 octreotide implant 64 mutated KRAS gene 64 MyVax ® 64 Cell Lymphoma 64 demethylating agent 64 unresectable locally advanced 64 Allovectin 7 ® 64 nonsmall cell lung cancer 64 Atypical Hemolytic Uremic Syndrome 64 Taxotere ® 64 metastatic renal 64 rilonacept 64 Phase #b/#a clinical 64 KRAS wild 63 recurrent GBM 63 IMiDs ® compound 63 tumor lysis syndrome 63 myeloproliferative disorders 63 nucleoside analog 63 RSR# 63 personalized immunotherapy 63 lymphomas leukemias 63 hepatitis C HCV 63 Initiate Clinical Trial 63 Alemtuzumab 63 multicenter Phase II 63 MET inhibitor 63 Vitaxin 63 BRAF V#E mutation 63 refractory gout 63 CIMZIA ™ 63 secondary hyperparathyroidism 63 pancreatic islet cell 63 #I TM# 63 pancreatic neuroendocrine tumors 63 Panzem R 63 registrational trial 63 etanercept Enbrel 63 non resectable metastatic 63 evaluating REVLIMID 63 patientswith 63 Renal Cell Carcinoma RCC 63 HDAC Inhibitor 63 commercialize deforolimus 63 Zavesca R 63 vascular disrupting agents 63 acute lymphoblastic 63 alemtuzumab Campath 63 pegylated interferon alpha 63 BRAF V#E 63 metastatic castration resistant 63 hematologic disorders 63 vapreotide acetate 63 paclitaxel poliglumex 63 CEQ# 63 Phase Ib II 63 Acute Myeloid Leukaemia AML 63 cyclophosphamide chemotherapy 63 Glioblastoma Multiforme 63 nucleotide analog 63 chlorambucil 63 angiogenesis inhibitor 63 PEGylated anti 63 axitinib 63 davunetide intranasal AL 63 primary immunodeficiency PI 63 Ozarelix 63 advanced carcinoid 63 constipation OIC 63 recurrent malignant glioma 63 coagulation disorders 63 Hormone Refractory Prostate Cancer 63 immunotherapeutic vaccine 63 vinorelbine tartrate 63 ibritumomab tiuxetan 63 Tyrosine Kinase Inhibitor 63 Alequel 63 Ixempra 63 hormone LHRH 63 myeloproliferative 63 prokinetic agent 63 null responder 63 lung pancreatic 63 Lenalidomide 63 relapsed acute myelogenous 63 heavily pretreated 63 chronic granulomatous disease 63 antigen CD# 63 Arcalyst 63 AQ4N 63 adult mesenchymal stem 63 Myocet 63 lexidronam injection 63 topically administered 63 prostate cancer AIPC 63 INSPIRE Trial Phase III 63 targeting CD# 63 poly ADP ribose polymerase 63 Targretin capsules 63 Anti VEGF 63 leukemia APL 63 radiotherapeutic 63 vemurafenib 63 relapsed mantle 63 Increlex ® 63 antisense inhibitors 63 Temsirolimus 63 relapsing multiple sclerosis 63 RoACTEMRA 63 mutated K ras 63 Traficet EN 63 eosinophilic asthma 63 Neo Bladder Augment 63 antiproliferative effects 63 chronic thromboembolic pulmonary 63 IMiD 63 Sezary syndrome 63 Everolimus 63 Pharmacokinetics PK 63 severe oral mucositis 63 familial amyloidotic polyneuropathy FAP 63 basal cell carcinoma BCC 63 MabThera Rituxan 63 selective modulator 63 MT#/MEDI-# 63 acute HAE attacks 63 Safinamide 63 nilotinib 63 LymphoStat B TM 63 cathepsin K inhibitor 63 PEG interferon 63 PAOD 63 AMPK activators 63 recombinant enzyme 63 Nicole Onetto MD 63 MabCampath 63 retinal vein occlusion induced 63 cisplatin resistant 63 EGFR inhibitors 63 Dasatinib 63 entinostat 63 neratinib 63 EGFr 63 phase IIb trial 63 thymidylate synthase TS 63 factor G CSF 63 Xyfid TM 63 unresectable tumors 63 ALK inhibitors 63 LBH# 63 transplantation HCT 63 ACZ# 63 lorvotuzumab mertansine 63 Torisel temsirolimus 63 effector function 63 tyrosine kinase inhibitors TKIs 63 acadesine 63 rituximab Rituxan 63 cediranib 63 acute GvHD 63 MEK inhibitor 63 polycythemia vera PV 63 initiated Phase Ib 63 Li Fraumeni Syndrome 63 MALT lymphoma 63 Zorbtive TM 63 anthracyclines taxanes 63 protein tyrosine phosphatase 1B 63 denileukin diftitox 63 relapsed refractory aggressive 63 indolent follicular non 63 BRAF inhibitors 63 Pivotal Phase III 63 follicular non 63 CA9 SCAN 63 Epirubicin 63 CD# CEA 63 mTOR inhibitors 63 FLT3 63 APOPTONE 63 ocrelizumab 63 lesional 63 pediatric malignancies 63 p# inhibitor 63 evaluating tivozanib 63 prostate cancer HRPC 63 TNF Tumor Necrosis Factor 63 fludarabine cyclophosphamide 63 chemosensitizer 63 motesanib diphosphate 63 fallopian tube carcinoma 63 orally bioavailable 63 PDE# inhibitors 63 RhuDex R 63 humanized monoclonal 63 Cryopyrin Associated Periodic Syndromes 63 glufosfamide 63 AA amyloidosis 63 rituximab refractory follicular 63 Vidaza ® 63 trastuzumab DM1 63 5 fluorouracil leucovorin 63 K ras mutations 63 p# MAP kinase inhibitor 63 PEG IFN 63 HBeAg negative patients 63 receptor blocker 63 CVP cyclophosphamide vincristine 63 orphan medicinal product 63 Idiopathic Pulmonary Fibrosis 63 pharmacokinetic PK study 63 Thrombin 63 BENLYSTA ® 63 idiopathic pulmonary fibrosis IPF 63 lenalidomide dexamethasone 63 mCRPC 63 ceftazidime 63 Romidepsin 63 OMAPRO 63 Revlimid lenalidomide 63 Ocrelizumab 63 XL# XL# 63 Dapagliflozin 63 Heterozygous Familial Hypercholesterolemia 63 OvaRex MAb 63 Interferon alpha 63 Brentuximab Vedotin SGN 63 gastric adenocarcinoma 63 P#X# antagonist 63 plus gemcitabine 63 plasma kallikrein inhibitor 63 AA Amyloidosis 63 ALK inhibitor 63 selectively inhibited 63 OncoVEX GM CSF 63 TNF antagonist 63 BRIM3 63 OSI Tarceva 63 BRAF mutant 63 PROCHYMAL 63 TELINTRA 63 JAK inhibitors 63 neovascular 63 anti EGFR antibody 63 atypical hemolytic uremic syndrome 63 Vectibix panitumumab 63 evaluating Prochymal 63 VEGF inhibitors 63 antitumor effect 63 oral ridaforolimus 63 dose escalation clinical 63 oral deforolimus 63 goserelin 63 LHRH antagonist 63 retinal vein occlusion 63 chronic HBV 63 PEGylated interferon beta 1a 63 Abiraterone acetate 63 Davanat 63 cisplatin gemcitabine 63 Removab 63 T1c 63 VEGFR2 inhibitor 63 CIMZIA TM 63 FK# 63 angiogenesis inhibition 63 localized renal 63 atypical Hemolytic Uremic Syndrome 63 zanolimumab 63 FOLFOX6 63 Noxafil 63 Hedgehog antagonist 63 stage IIIB 63 temsirolimus 63 Nilotinib 63 antimitotic 63 GVAX ® 63 accumulate preferentially 63 invasive aspergillosis 63 FUSILEV enhances 63 EGFR HER 63 Yondelis ® 63 mutated KRAS 63 herpetic keratitis 63 bexarotene 63 pouchitis 63 NSCLC tumors 63 kinase inhibition 63 monoclonal antibody IgG1 Mab 63 Bezielle 63 lymphocytosis 63 Neuvenge 63 Tesmilifene 63 GRN# 63 renal cell carcinoma 63 hematological indications 63 satraplatin Phase 63 Phase IIIb clinical 63 Mepact 63 vinorelbine 63 recombinant factor VIIa 63 ALN TTR 62 NAGS deficiency 62 gastrin analogue TT 62 oral picoplatin 62 fallopian tube cancers 62 null responder HCV 62 HGS# 62 incyclinide 62 cardiotoxic 62 thymalfasin 62 FOLFIRI chemotherapy 62 Lambert Eaton Myasthenic 62 castration resistant prostate cancer 62 choroidal vasculopathy 62 NSCL cancer 62 azacitidine 62 Tykerb lapatinib 62 complete cytogenetic response 62 BCG refractory carcinoma 62 pomalidomide 62 compound AEZS 62 Rituximab 62 Severe Sepsis 62 recurrent herpes labialis 62 Actimmune ® 62 chronic eosinophilic leukemia 62 GA GCB 62 midstage trials 62 RRM1 62 rALLy 62 inhaled liposomal ciprofloxacin 62 Solazed 62 IGF 1R inhibitor 62 Myelodysplastic Syndrome 62 inhibitor RG# 62 taxane resistant 62 EGFR expressing 62 HCV protease inhibitors 62 sitaxsentan 62 LHRH analogues 62 adalimumab Humira 62 diabetic gastroparesis 62 miconazole Lauriad 62 PEGylated interferon 62 Bayer Nexavar 62 Ofatumumab 62 Tamibarotene 62 vismodegib 62 PrevOnco ™ 62 deletion 5q 62 investigational oral hepatitis C 62 whose tumors overexpress 62 Chronic Myelogenous Leukemia CML 62 Pivotal Study 62 lenalidomide Revlimid 62 hormone refractory prostate cancer 62 induces apoptosis 62 refractory prostate cancer 62 Vaprisol 62 alpha#beta# integrin 62 BRAF mutation 62 cholangiocarcinoma 62 refractory ovarian cancer 62 Microplasmin 62 antiangiogenic therapy 62 Folfox 62 Diamyd ® 62 Bosutinib 62 investigational humanized monoclonal antibody 62 Proleukin 62 cisplatin vinorelbine 62 gemcitabine Gemzar R 62 Nanobody 62 Phase #/#a trial 62 renal carcinoma 62 R Saizen R 62 Intravenous CP 62 JAK3 62 pentostatin 62 Adjuvant Treatment 62 dexanabinol 62 Alzhemed TM 62 adecatumumab MT# 62 MELAS 62 Onalta 62 subcutaneous methylnaltrexone 62 Myelofibrosis 62 mGluR2 NAM 62 sarcomatoid 62 ONCASPAR 62 ® bortezomib 62 myelofibrosis polycythemia vera 62 Zevalin R Ibritumomab 62 hepatocellular carcinoma 62 ® lenalidomide 62 NP2 Enkephalin 62 anticancer compound 62 DEB# 62 vaccines oncolytic virus 62 MORAb 62 Pyridorin 62 HIF PHI 62 Telatinib 62 chronic ITP patients 62 oral antiviral 62 hematological cancers 62 breast carcinoma 62 syngeneic 62 HER2 overexpression 62 azacytidine 62 pediatric Crohn disease 62 EVIZON TM 62 docetaxel chemotherapy 62 terlipressin 62 immune modulator 62 advanced nonsquamous NSCLC 62 hematologic malignancies 62 bardoxolone methyl 62 Vicinium TM 62 XYOTAX TM 62 Sanvar R 62 refractory AML 62 PDE4 inhibitor 62 recurrent glioblastoma multiforme GBM 62 CD8 + cytotoxic 62 PI3K inhibitors 62 MDS AML 62 Philadelphia Chromosome Positive 62 symptomatic BPH 62 benign prostatic hypertrophy BPH 62 ALN PCS 62 cancer mCRC 62 Meets Primary Endpoint 62 generation antisense inhibitor 62 Orencia abatacept 62 capecitabine Xeloda 62 non Hodgkin lymphomas 62 A3 adenosine receptor 62 Denufosol 62 untreated metastatic melanoma 62 M2 subunit 62 OvaRex R 62 irinotecan oxaliplatin 62 HuMax TAC 62 antifibrotic 62 murine model 62 orally inhaled migraine 62 GMX# 62 midstage clinical 62 Natalizumab 62 hoFH 62 non splenectomized 62 Gefitinib 62 CALGB # [002] 62 genomic biomarker 62 smoldering myeloma 62 RH1 62 trastuzumab DM1 T DM1 62 paclitaxel Taxol 62 Exherin TM 62 hyperphenylalaninemia HPA due 62 progressive metastatic prostate 62 EGFR TKIs 62 pamidronate 62 Immunotherapeutic 62 CCR5 antagonist 62 unresectable 62 dexpramipexole 62 Rheumatoid Arthritis RA